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INTRODUCTION
Patients generally have chemotherapy after surgery for can-
cer, regardless of its stage. Chemotherapy usually causes sev-
eral side effects, such as nausea, hair loss, and fatigue. The cen-
tral nervous system is relatively safe from such toxicity because 
the blood-brain barrier protects it, and it has a slower cell pro-
liferation rate. Nevertheless, chemotherapy agents can cause 
neurological and psychiatric complications. 
Introduced in 1958, 5-Fluorouracil (5-FU) is one of the most 
common chemotherapeutic agents. It has been widely used 
to treat solid organ tumors, such as tumors of the colon, rec-
tum, breast, pancreas, and stomach. Its usual side effects are 
gastrointestinal symptoms, alopecia, cardiotoxicity, and neu-
tropenia. Although neuropsychiatric complications have not 
been common, physicians have reported leukoencephalopa-
thy,
1 depression,
2 organic mental disorder,
3 psychosis,
4 and ma-
nia
5 as side effects. 
We report the case of a woman who developed an acute ma-
nic episode after receiving 5-FU chemotherapy during treat-
ment for rectal cancer. 
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CASE
In January 2010, a 77-year-old female underwent a colonos-
copy due to an intermittent anal bleeding episode. The test 
found a rather freely-movable, 1 cm ulcerofungating mass in 
the left anterior side of the anus, 1 cm above the anal verge. Co-
lonoscopic biopsy confirmed an adenocarcinoma. There was 
no sign of metastasis in her abdominal computed tomography 
(CT) or whole body positron emission tomography scan. On 
January 18, 2010, she underwent a transanal local excision un-
der general anesthesia. The final pathology revealed a submu-
cosal invasion by the tumor and a lymphatic invasion by tumor 
cells. However, the patient and her family declined a further 
curative radical surgery. Therefore, we recommended adjuvant 
radiotherapy and chemotherapy as the alternative manage-
ment. She received radiotherapy, scheduled as 28 sessions, 
whole-pelvis at 4,500 cGy and tumor bed boost at 540 cGy, 
from February 9th to March 22nd. During the same period, 
she received intravenous chemotherapy, in the form of 790 mg 
(500 mg/m
2) fluorouracil (5-FU) and 32 mg (20 mg/m
2) cal-
cium folinate, for 5 consecutive days at 3-week intervals. St-
arting February 16th, she also received the antiemetic ondan-
setron. 
After her 4th 5-FU and folinate calcium chemotherapy cy-
cle on May 15th, her behavior changed rapidly. That evening, 
her mood was elated and talkative. She called a friend and 
asked to visit in the middle of night, around 3 am. Her voice 
became louder and her need to sleep decreased. The next day, 
she was still anxious and talkative as compared to her previous 
character. She became more impulsive and sometimes offered 
verbal assaults. Her mood was labile, and she wrote a will and 
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then insisted that she was superior to the president of the Re-
public of Korea. Her family took her a local clinic, which gave 
her a sedative, but her mood and behavior displayed no re-
markable improvement. 
Finally, she came to the hospital, and the staff surgeon con-
sulted the psychiatrist, who decided to admit her on May 25th. 
She had no family history of psychiatric illness or previous his-
tory of psychiatric treatment. On admission, her conscious-
ness was clear, and orientation was intact. Her mood was elat-
ed, euphoric, and labile. Her pressure of speech and inattention 
made it difficult to carry out her interview. She was easily dis-
tracted by environmental stimuli and expressed energetic in-
terest in the psychiatric ward. She had grandiose delusions, 
such as insisting she was stronger than the president of the Re-
public of Korea was. There was no evidence of auditory or vi-
sual hallucinations. Her neurological examination was nor-
mal. A brain magnetic resonance imaging (MRI) showed no 
evidence of metastasis or any signs of acute infarct or hemor-
rhage. There were chronic infarcts in the right frontal peri-
ventricular white matter and several small, chronic, ischemic 
foci in the subcortical white matter on both sides. These find-
ings did not match her psychiatric symptoms. A routine blood 
test showed mild anemia (Hb=10.7 g/dL). 
Our diagnostic impression was secondary manic episode 
due to substance (ICD-10 diagnosis, organic manic disorder 
F06.30). We prescribed olanzapine (5 mg/day), divalproex so-
dium (250 mg/day), and lorazepam (2 mg/day). Then, after she 
had been hospitalized 5 days, we increased the dose to 10 mg 
olanzapine and 1,000 mg divalproex sodium. We discontin-
ued the lorazepam after the 2nd day. She was still in a manic 
state, with hyperactivity, grandiose ideation, insomnia, and 
labile mood. After her 10th day in the hospital, we increased her 
medication to 20 mg/day olanzapine and 1,000 mg/day dival-
proex sodium. After this 10th day, her mood gradually calmed 
down, and she started to sleep without interruption or extra 
medication. She could partially recall her symptomatic behav-
iors of 2 weeks ago and expressed feelings of shame. We de-
creased her medication to 15 mg/day olanzapine and 1,000 
mg/day divalproex sodium. She gradually returned to a nor-
mal range of moods, sleep pattern, and psychomotor speed. 
We conducted psychological tests during her admission day. 
Her IQ was average (total score=98), and her attention span 
and executive functioning were within normal ranges. The Ben-
der-Gestalt test revealed no sign of organic brain damage. 
Minnesota Multiphasic Personality Inventory profile showed 
hyperactivity and a higher energy level, as the increased 9th 
factor.
On June 19th, she left the hospital with the manic episode 
in full remission. She did not show any extraordinary behav-
ior, flight of ideas, or cognitive deficits. Her final medication 
was olanzapine, 10 mg/day, and divalproate, 1,000 mg/day. Al-
though she was scheduled to undergo more chemotherapy, 
she and her family declined this idea, and her physician re-
spected their decision. She visited the outpatient clinic one 
week and again one month after discharge. Her mood remain-
ed stable and euthymic. She had been taking her medications, 
with olanzapine at 5 mg/day and divalproex sodium still 1,000 
mg/day. Her manic episode was still in remission. We sched-
uled her to receive the medication for several months, to pre-
vent a possible relapse.
DISCUSSION
Though the patient received additional folinate calcium and 
ondansetron, we did not assume they were directly associat-
ed with her development of manic symptoms. As radiothera-
py was limited to the rectal lesion, it could not affect the cen-
tral nervous system. Therefore, the chemotherapy series using 
5-FU was associated with her abrupt manic episode. 
Fluorouracil’s mechanism of action blocks DNA synthesis 
by decreasing thymidine monophosphate formation through 
the inhibition of thymidylate synthetase. As 5-FU can easily pe-
netrate the blood-brain barrier, it is reportedly associated with 
several neurological complications, including parkinsonian 
syndrome, oculomotor disturbance, and peripheral neuropa-
thy.
1 The ending metabolite of 5-FU is fluorocitrate; we re-
garded its inhibition of aconitase in the Krebs cycle, resulting 
in citrate accumulation in the neurons, as the neurotoxicity me-
chanism.
6 Fluorouracil itself did not correlate with the neu-
rotoxicity.
7 Previous cases studies reported leukoencephalop-
athy in brain CTs. However, this case showed no evidence of 
leukoencephalopathy on a brain MRI. We attribute her vul-
nerability to psychiatric symptoms to her age, because 5-FU 
side effects are common in the elderly.
8 
Accumulation of 5-FU is one possible cause of such a secon-
dary manic episode, via injury to several brain structures and 
neurotransmitter pathways. Secondary mania should be di-
agnosed in a case of no previous affective illness history and 
no confusional state. This patient’s onset age was consider-
ably older than the typical age for a primary manic episode.
9 
There are several possible mechanism related to secondary 
mania. First, it can develop after a neuronal injury focuses on 
right side limbic area lesion. And the right basotemporal and 
orbitofrontal cortex area is more likely to correlate with a bipo-
lar episode, whereas a right side cortical injury alone occurs 
in association with unipolar secondary mania.
10 An orbito-
frontal cortex lesion can cause development of irritability, la-
bile mood, euphoria, and inappropriate social behavior.
11 
Additionally, dysfunction of the hypothalamic area can lead 
to insomnia and dysregulation of appetite and sleep.
12 At the JH Ha et al. 
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neurotransmission level, the interactions of serotonin, dopa-
mine, norepinephrine, and acetylcholine through the orbito-
frontal-subcortical network are associated with development 
of manic symptoms.
9
Based on these research findings, we thought that 5-FU’s 
neurotoxicity accumulated during the 4 chemotherapy cycles, 
then a subtle change in the orbitofrontal-subcortical network, 
correlated with the dopamine and serotonin system, and re-
versible damage to the right cortical and limbic area caused a 
rapid manic episode. The manic episode subsided after dis-
continuation of 5-FU and administration of antipsychotic 
drugs. Furthermore, we thought the additional factors, such 
as her lack of any record of previous mood episodes, her rapid 
remission, the reversibility of her symptoms, and lack of cog-
nitive change showed the manic episode developed due to an 
exogenous substance. Moreover, 5-FU-related neurotoxicity 
is dose- and schedule-dependent and reversible upon discon-
tinuation of the medication.
1 
We reported that the chemotherapeutic agent 5-FU can in-
duce, not only neurological symptoms, but also psychiatric 
symptoms. Clinicians need to consider the possible develop-
ment of psychosis or mood symptoms in cases of 5-FU usage. 
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